Cargando…

The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel

AIMS: Randomized controlled trials have shown that insulin glargine 300 U/mL (Gla‐300) has a more stable and prolonged glucose lowering effect among patients with type 2 diabetes (T2DM) compared to insulin glargine 100 U/mL (Gla‐100), resulting in a reduced risk of hypoglycaemia while maintaining a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melzer Cohen, Cheli, Banon, Tamar, Shalev, Varda, Chodick, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375096/ https://www.ncbi.nlm.nih.gov/pubmed/32704550 http://dx.doi.org/10.1002/edm2.124

Ejemplares similares

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
por: Galstyan, Gagik R., et al.
Publicado: (2022)

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
por: Lindauer, Klaus, et al.
Publicado: (2019)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo(®)) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
por: Wiesli, Peter, et al.
Publicado: (2018)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
por: Becker, R H A, et al.
Publicado: (2015)

Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
por: de Galan, Bastiaan E
Publicado: (2016)

Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
por: Maffeis, Claudio, et al.
Publicado: (2022)

In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
por: Schiavon, Michele, et al.
Publicado: (2020)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

SUN-LB126 Real-World Safety and Effectiveness of Insulin Glargine 300 U/ML (Gla-300) in People With Type 2 Diabetes Who Fast During Ramadan
por: Hassanein, Mohamed, et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
por: Thomann, Robert, et al.
Publicado: (2020)

Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study
por: Ragonese, Mauro, et al.
Publicado: (2020)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
por: Miller, Michelle, et al.
Publicado: (2021)

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial
por: Ji, Linong, et al.
Publicado: (2019)

Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
por: Vargas-Uricoechea, Hernando
Publicado: (2018)

Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)
por: Bailey, Timothy S., et al.
Publicado: (2019)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
por: Bolli, G B, et al.
Publicado: (2015)

Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes after failure of oral therapy in a real‐world setting
por: Pfohl, Martin, et al.
Publicado: (2020)

Real‐world effectiveness and safety of insulin glargine 300 U/ml in insulin‐naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS
por: Vargas‐Uricoechea, Hernando, et al.
Publicado: (2022)

Real-World Treatment Patterns and Outcomes of Growth Hormone Treatment Among Children in Israel Over the Past Decade (2004–2015)
por: Ben-Ari, Tal, et al.
Publicado: (2021)

Real-World Use of Alirocumab: Experience from a Large Healthcare Provider
por: Elis, Avishay, et al.
Publicado: (2023)

Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
por: Mader, Julia K, et al.
Publicado: (2022)

SAT-281 Relationship between Socioeconomic Status, Adherence and Outcomes to Growth Hormone Treatment in Children: Real-World Treatment Patterns in Israel
por: Ben-Ari, Tal, et al.
Publicado: (2019)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
por: Pohlmeier, Harald, et al.
Publicado: (2017)

Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study
por: Escalada, Javier, et al.
Publicado: (2020)

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
por: Pettus, Jeremy, et al.
Publicado: (2019)

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
por: Home, Philip D., et al.
Publicado: (2017)

Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis
por: Nakanishi, Shuhei, et al.
Publicado: (2018)

Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme
por: Blonde, Lawrence, et al.
Publicado: (2021)

Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures
por: Lingvay, Ildiko, et al.
Publicado: (2017)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020)

Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
por: Harris, Stewart B., et al.
Publicado: (2022)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
por: Oya, Junko, et al.
Publicado: (2021)

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
por: Ritzel, R, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ccn9isq9desck3ddg1btapgbkk